PHARMACEUTICAL COMPOSITIONS COMPRISING AZD9291
First Claim
Patent Images
1. A pharmaceutical composition comprising:
- (a) from 2 to 70 parts of the Agent;
(b) from 5 to 96 parts of two or more pharmaceutical diluents;
(c) from 0 to 15 parts of one or more pharmaceutical disintegrants;
(d) from 0 to 1.5 parts of one or more pharmaceutical solubilising agents; and
(e) from 0 to 3 parts of one or more pharmaceutical lubricants;
wherein all parts are by weight and the sum of the parts (a)+(b)+(c)+(d)+(e)=100;
wherein one of the two or more pharmaceutical diluents is microcrystalline cellulose wherein the microcrystalline cellulose makes up from 7 to 30 wt % of the two or more pharmaceutical diluents (b); and
wherein the Agent is N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3 -yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide or a pharmaceutically acceptable salt thereof.
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to pharmaceutical compositions suitable for oral administration, and more particularly to pharmaceutical compositions, including pharmaceutical tablet compositions, containing N-(2-{2-dimethylaminoethyl-methyl-amino}-4-methoxy-5-[4-(1-methylindol-3-yppyrimidin-2-yl]amino phenyl)prop-2-enamide (“AZD9291”) or a pharmaceutically Cacceptable salt thereof, wherein such compositions comprise a certain amount of microcrystalline cellulose and at least one other pharmaceutical diluent.
4 Citations
14 Claims
-
1. A pharmaceutical composition comprising:
-
(a) from 2 to 70 parts of the Agent; (b) from 5 to 96 parts of two or more pharmaceutical diluents; (c) from 0 to 15 parts of one or more pharmaceutical disintegrants; (d) from 0 to 1.5 parts of one or more pharmaceutical solubilising agents; and (e) from 0 to 3 parts of one or more pharmaceutical lubricants; wherein all parts are by weight and the sum of the parts (a)+(b)+(c)+(d)+(e)=100;
wherein one of the two or more pharmaceutical diluents is microcrystalline cellulose wherein the microcrystalline cellulose makes up from 7 to 30 wt % of the two or more pharmaceutical diluents (b); and
wherein the Agent is N-(2-{2-dimethylaminoethyl-methylamino}-4-methoxy-5-{[4-(1-methylindol-3 -yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide or a pharmaceutically acceptable salt thereof.- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)
-
Specification